Drug Approval | February 28, 2022
China’s NMPA accepts supplemental NDA for Carteyva
The sNDA was supported by the clinical results from cohort B of a single-arm, multi-center, pivotal study (RELIANCE study) on Carteyva in adult patients with relapsed or refractory B cell non-hodgkin lymphoma in China
_256_275.jpeg)
